http://purl.org/np/RAzOMmCJBYu1Oo2-dM66bxsVH7gPP4DavFSPfPs-vQhbE#Head
http://purl.org/np/RAzOMmCJBYu1Oo2-dM66bxsVH7gPP4DavFSPfPs-vQhbE
http://www.nanopub.org/nschema#hasAssertion
http://purl.org/np/RAzOMmCJBYu1Oo2-dM66bxsVH7gPP4DavFSPfPs-vQhbE#assertion
http://purl.org/np/RAzOMmCJBYu1Oo2-dM66bxsVH7gPP4DavFSPfPs-vQhbE
http://www.nanopub.org/nschema#hasProvenance
http://purl.org/np/RAzOMmCJBYu1Oo2-dM66bxsVH7gPP4DavFSPfPs-vQhbE#provenance
http://purl.org/np/RAzOMmCJBYu1Oo2-dM66bxsVH7gPP4DavFSPfPs-vQhbE
http://www.nanopub.org/nschema#hasPublicationInfo
http://purl.org/np/RAzOMmCJBYu1Oo2-dM66bxsVH7gPP4DavFSPfPs-vQhbE#pubinfo
http://purl.org/np/RAzOMmCJBYu1Oo2-dM66bxsVH7gPP4DavFSPfPs-vQhbE
http://www.w3.org/1999/02/22-rdf-syntax-ns#type
http://www.nanopub.org/nschema#Nanopublication
http://purl.org/np/RAzOMmCJBYu1Oo2-dM66bxsVH7gPP4DavFSPfPs-vQhbE#assertion
http://purl.obolibrary.org/obo/DOID_224
https://w3id.org/biolink/vocab/category
https://w3id.org/biolink/vocab/Disease
http://purl.org/np/RAzOMmCJBYu1Oo2-dM66bxsVH7gPP4DavFSPfPs-vQhbE#association
http://www.w3.org/1999/02/22-rdf-syntax-ns#object
http://purl.obolibrary.org/obo/DOID_224
http://purl.org/np/RAzOMmCJBYu1Oo2-dM66bxsVH7gPP4DavFSPfPs-vQhbE#association
http://www.w3.org/1999/02/22-rdf-syntax-ns#predicate
https://w3id.org/biolink/vocab/treats
http://purl.org/np/RAzOMmCJBYu1Oo2-dM66bxsVH7gPP4DavFSPfPs-vQhbE#association
http://www.w3.org/1999/02/22-rdf-syntax-ns#subject
https://identifiers.org/drugbank:DB06209
http://purl.org/np/RAzOMmCJBYu1Oo2-dM66bxsVH7gPP4DavFSPfPs-vQhbE#association
http://www.w3.org/1999/02/22-rdf-syntax-ns#type
http://www.w3.org/1999/02/22-rdf-syntax-ns#Statement
http://purl.org/np/RAzOMmCJBYu1Oo2-dM66bxsVH7gPP4DavFSPfPs-vQhbE#association
http://www.w3.org/2000/01/rdf-schema#label
"* Active pathological bleeding ( 4.1 4.2 4.3 Prasugrel tablets are contraindicated in patients with active pathological bleeding such as peptic ulcer or intracranial hemorrhage [see Warnings and Precautions ( 5.1 6.1 Prasugrel tablets is contraindicated in patients with a history of prior transient ischemic attack (TIA) or stroke. In TRITON-TIMI 38 (TRial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition with Prasugrel), patients with a history of TIA or ischemic stroke (>3 months prior to enrollment) had a higher rate of stroke on Prasugrel tablets (6.5%; of which 4.2% were thrombotic stroke and 2.3% were intracranial hemorrhage [ICH]) than on clopidogrel (1.2%; all thrombotic). In patients without such a history, the incidence of stroke was 0.9% (0.2% ICH) and 1.0% (0.3% ICH) with Prasugrel tablets and clopidogrel, respectively. Patients with a history of ischemic stroke within 3 months of screening and patients with a history of hemorrhagic stroke at any time were excluded from TRITON-TIMI 38. Patients who experience a stroke or TIA while on Prasugrel tablets generally should have therapy discontinued [see Adverse Reactions ( 6.1 14 Prasugrel tablets is contraindicated in patients with hypersensitivity (e.g., anaphylaxis) to prasugrel or any component of the product [see Adverse Reactions ( 6.2"
http://purl.org/np/RAzOMmCJBYu1Oo2-dM66bxsVH7gPP4DavFSPfPs-vQhbE#association
https://w3id.org/biolink/vocab/provided_by
https://w3id.org/um/NeuroDKG
http://purl.org/np/RAzOMmCJBYu1Oo2-dM66bxsVH7gPP4DavFSPfPs-vQhbE#association
https://w3id.org/biolink/vocab/relation
https://schema.org/MedicalContraindication
https://identifiers.org/drugbank:DB06209
https://w3id.org/biolink/vocab/category
https://w3id.org/biolink/vocab/Drug
http://purl.org/np/RAzOMmCJBYu1Oo2-dM66bxsVH7gPP4DavFSPfPs-vQhbE#provenance
http://purl.org/np/RAzOMmCJBYu1Oo2-dM66bxsVH7gPP4DavFSPfPs-vQhbE#assertion
http://www.w3.org/ns/prov#wasAttributedTo
https://orcid.org/0000-0002-1468-3557
http://purl.org/np/RAzOMmCJBYu1Oo2-dM66bxsVH7gPP4DavFSPfPs-vQhbE#pubinfo
http://purl.org/np/RAzOMmCJBYu1Oo2-dM66bxsVH7gPP4DavFSPfPs-vQhbE#sig
http://purl.org/nanopub/x/hasAlgorithm
RSA
http://purl.org/np/RAzOMmCJBYu1Oo2-dM66bxsVH7gPP4DavFSPfPs-vQhbE#sig
http://purl.org/nanopub/x/hasPublicKey
MIGfMA0GCSqGSIb3DQEBAQUAA4GNADCBiQKBgQCODwZkXojpEKwk7Ldj2oPPfCstvqrcpgCaTLo235K7ht9C7E1GCkLvUuL2b4VWXJTcZx/hxgDauR8hUeYq/lS6tfTL9yFZsnfl+PWYDyz7vv6N+wJVx2LL8bO6ntCjcOzvW2t2WUeF12Sb6b3I6uOYP0N8iQKts1WasY/yEYKAHQIDAQAB
http://purl.org/np/RAzOMmCJBYu1Oo2-dM66bxsVH7gPP4DavFSPfPs-vQhbE#sig
http://purl.org/nanopub/x/hasSignature
a7/H+AvkeDkIrMj9ymhEqSr5x182wkUxWk22OLLMrpAny1MY/RjC48HiSljXs5Qs8K8ioxbAQLMZU8St2Xf2s1c+/5ngtPrGymx5WDaxlQpIeuPLb7aKrNTYso/ePXP79LzpW3zvtcdI0r3u9wNH6ThPcyVIqpZHe3mBMeBQrO8=
http://purl.org/np/RAzOMmCJBYu1Oo2-dM66bxsVH7gPP4DavFSPfPs-vQhbE#sig
http://purl.org/nanopub/x/hasSignatureTarget
http://purl.org/np/RAzOMmCJBYu1Oo2-dM66bxsVH7gPP4DavFSPfPs-vQhbE
http://purl.org/np/RAzOMmCJBYu1Oo2-dM66bxsVH7gPP4DavFSPfPs-vQhbE
http://purl.org/dc/terms/created
2021-08-23T18:39:25.828+02:00
http://purl.org/np/RAzOMmCJBYu1Oo2-dM66bxsVH7gPP4DavFSPfPs-vQhbE
http://purl.org/dc/terms/creator
https://orcid.org/0000-0002-1468-3557
http://purl.org/np/RAzOMmCJBYu1Oo2-dM66bxsVH7gPP4DavFSPfPs-vQhbE
https://w3id.org/np/o/ntemplate/wasCreatedFromProvenanceTemplate
http://purl.org/np/RANwQa4ICWS5SOjw7gp99nBpXBasapwtZF1fIM3H2gYTM
http://purl.org/np/RAzOMmCJBYu1Oo2-dM66bxsVH7gPP4DavFSPfPs-vQhbE
https://w3id.org/np/o/ntemplate/wasCreatedFromPubinfoTemplate
http://purl.org/np/RAA2MfqdBCzmz9yVWjKLXNbyfBNcwsMmOqcNUxkk1maIM
http://purl.org/np/RAzOMmCJBYu1Oo2-dM66bxsVH7gPP4DavFSPfPs-vQhbE
https://w3id.org/np/o/ntemplate/wasCreatedFromTemplate
http://purl.org/np/RAhNHZw6Urw_Mccs4qy6Ws3C9CRuaHpQx8AwuApbWkqnY